Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients – Results of the RESPECT-Study

Maximilian Weniger, John Moir, Marko Damm, Laura Maggino, Maximilian Kordes, Jonas Rosendahl, Güralp O. Ceyhan, Stephan Schorn, Daniel M. Schmid, Jan D’Haese, Stephan Böck, Stephan Krüger, Michael Haas, Falk Roeder, Marco Del Chiaro, Matthias Löhr, Domenico Tamburrino, Gaia Masini, Patrick Maisonneuve, Giuseppe Malleo, Roberto Salvia, Richard Charnley